Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics

被引：0

作者：

Jörg Mahlich

Kerstin Olbrich

Adrian Wilk

Antonie Wimmer

Claus Wolff-Menzler

机构：

[1] Health Economics and Outcomes Research,Düsseldorf Institute of Competition Economics (DICE)

[2] Janssen,Team Gesundheit

[3] Pharmaceutical Companies of Johnson & Johnson,Department of Psychiatry and Psychotherapy

[4] University of Düsseldorf,undefined

[5] Gesellschaft für Gesundheitsmanagement mbH,undefined

[6] Medical Affairs,undefined

[7] Janssen,undefined

[8] Pharmaceutical Companies of Johnson & Johnson,undefined

[9] University Medical Center Göttingen,undefined

[10] Georg-August-University,undefined

来源：

Clinical Drug Investigation | 2021年 / 41卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：99 / 113

页数：14

共 50 条

[41] Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?
Dooley, Kelly E.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (08) : 833 - 834
[42] A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia
Lin, Ching-Hua
Chen, Feng-Chua
Chan, Hung-Yu
Hsu, Chun-Chi
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2020, 28 (01): : 23 - 30
[43] COMPARING COMPLIANCE BY RACE AND ETHNICITY FOR SCHIZOPHRENIA PATIENTS ON ORAL OR LONG-ACTING INJECTABLE ANTIPSYCHOTICS
McLean, J.
Wei, Y.
VALUE IN HEALTH, 2024, 27 (06) : S326 - S326
[44] What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?
Stroup, T. Scott
JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (11) : 1261 - 1262
[45] NEW RESULTS ALTER BALANCE OF EVIDENCE IN META-ANALYSIS OF LONG-ACTING INJECTABLES VS. ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA
Kishimoto, Taishiro
SCHIZOPHRENIA RESEARCH, 2012, 136 : S58 - S58
[46] NEW RESULTS ALTER BALANCE OF EVIDENCE IN META-ANALYSIS OF LONG-ACTING INJECTABLES VS. ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA
Kishimoto, Taishiro
SCHIZOPHRENIA RESEARCH, 2012, 136 : S4 - S5
[47] Differences among long-acting antipsychotics in the maintenance treatment of schizophrenia
Kane, J.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 170 - 170
[48] Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia Practical Considerations
Kverno, Karan
Rozenberg, Ilya
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2021, 59 (07) : 7 - 12
[49] Importance of preventing relapse - benefits and place of long-acting injectables in treatment of schizophrenia
Taylor, D.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S758 - S758
[50] What role do long-acting injectables (LAIs) have in the treatment of schizophrenia?
Schreiner, A.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S632 - S632

← 1 2 3 4 5 →